[8-K] Unicycive Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Unicycive Therapeutics (UNCY) filed a Form 8-K stating it issued a press release announcing financial results for the three months ended September 30, 2025 and provided a business update. The press release is furnished as Exhibit 99.1. The company notes the information under Item 2.02, including Exhibit 99.1, is being furnished and not filed under Section 18 of the Exchange Act.

false 0001766140 0001766140 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40582		81-3638692
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		IRS Employer Identification No.)

4300 El Camino Real, Suite 210

Los Alto, CA 94022

(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 351-4495

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock		UNCY		Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Conditions.

On November 12, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1		Press Release of Unicycive Therapeutics, Inc. dated November 12, 2025.
104		Cover page interactive data file (formatted as Inline XBRL)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2025

	UNICYCIVE THERAPEUTICS, INC.
	By:	/s/ Shalabh Gupta
		Shalabh Gupta
		Chief Executive Officer

2

FAQ

What did UNCY announce in this Form 8-K?

UNCY issued a press release with financial results for the three months ended September 30, 2025 and provided a business update.

Where can I find the UNCY press release referenced?

It is included as Exhibit 99.1 to the Form 8-K.

Is the information considered filed or furnished?

The information under Item 2.02, including Exhibit 99.1, is furnished and not filed under Section 18 of the Exchange Act.

What period do the results cover for UNCY?

The press release covers the three months ended September 30, 2025.

What is Unicycive's trading symbol and exchange?

UNCY trades on the Nasdaq Capital Market under the symbol UNCY.

Which item of Form 8-K is used for the results?

The disclosure is under Item 2.02: Results of Operations and Financial Condition.